PMV PHARMACEUTICALS INC (PMVP)

US69353Y1038 - Common Stock

1.63  +0.05 (+3.16%)

After market: 1.63 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PMV PHARMACEUTICALS INC

NASDAQ:PMVP (7/15/2024, 7:03:56 PM)

After market: 1.63 0 (0%)

1.63

+0.05 (+3.16%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month1.24%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap83.85M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PMVP Daily chart

Company Profile

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company is headquartered in Princeton, New Jersey and currently employs 62 full-time employees. The company went IPO on 2020-09-25. p53 is a tumor suppressor protein, guardian of the genome, and normal or wild type, p53 has the ability to eliminate cancer cells. The Company’s lead product candidate, PC14586 is designed to bind to the mutation site and structurally correct the misfolded p53 protein, while sparing wild-type p53PC14586 has shown selective on-target activity, which primarily functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition (TGI), and tumor regression as a single agent. The firm has initiated a Phase I/II clinical trial for PC14586. In addition, it is also granted food and drug administration (FDA) Fast Track designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.

Company Info

PMV PHARMACEUTICALS INC

One Research Way

Princeton NEW JERSEY 08512

P: 16096426664

CEO: David H. Mack

Employees: 62

Website: https://www.pmvpharma.com/

PMVP News

News Image2 months ago - PMV Pharmaceuticals, Inc.Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today...

News Image2 months ago - Foundation MedicineFoundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
News Image2 months ago - BusinessInsiderPMVP Stock Earnings: PMV Pharma Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips PMV Pharma (NASDAQ:PMVP) just reported results for the first quarter of 2024.PM...

News Image2 months ago - InvestorPlacePMVP Stock Earnings: PMV Pharma Beats EPS for Q1 2024

PMVP stock results show that PMV Pharma beat analyst estimates for earnings per share the first quarter of 2024.

News Image2 months ago - PMV Pharmaceuticals, Inc.PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and...

News Image4 months ago - PMV Pharmaceuticals, Inc.PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS...

PMVP Twits

Here you can normally see the latest stock twits on PMVP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example